関連する実験動画
Updated: Sep 9, 2025
06:19
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
305
潰瘍性大腸炎患者における5-アミノサリチラトの離脱の結果: 断続的な治療の評価に向けた一歩
Ali Atay1, Mucahit Ergul1, Oguz Ozturk1
1Department of Gastroenterology, Ankara Bilkent City Hospital, Ankara 06800, Türkiye.
World journal of gastroenterology
|September 4, 2025
まとめ
潰瘍性大腸炎 (UC) 患者の治療を中止すると,2年以内に40%の患者で再発が起こりました. しかし,ほとんどの再発は,5 - ASAの再投与で成功しました.
科学分野:
- 胃腸内科
- 臨床薬局
- 炎症性腸疾患の研究
背景:
- 5- アミノサリシル酸 (5- ASA) は,軽度から中度までの潰瘍性大腸炎 (UC) の基礎療法です.
- 5ASA維持療法はUC再発と結腸直腸がんのリスクを減らすために確立されています.
- 5- ASAの離脱の結果を理解することは,治療の順守戦略にとって極めて重要です.
研究 の 目的:
- 5 - アミノサリシル酸 (5- ASA) の単独治療を中止した潰瘍性大腸炎 (UC) 患者の臨床的アウトカムを評価する.
- 5ASAの離脱後の再発率と,その後の管理戦略を決定する.
主な方法:
- 5- ASA単独療法で寛解した成人UC患者で,不服従のために治療を中止した後の分析.
- 2019年7月から2025年4月までの患者のスクリーニング,再発率と管理に関するフォローアップ.
- 再発した患者と再発していない患者の人口統計学,臨床,生化学的パラメータの比較
主要な成果:
- 880人のUC患者のうち,30人 (3. 4%) が不適合のため5- ASAを離脱した.
- 12人の患者 (40%) は中位20ヶ月後に再発した.
- 寛解率は1年目89%から3年目64%に減少した.
結論:
- 断続的な5- ASA治療は,UC患者,特に長期間寛解した患者にとって安全で実行可能である.
- 治療を最大1年間中断することは許容可能であり,ほとんどの再発は5-ASAを再導入することによって管理できます.
- これは,5 - ASAの柔軟な投与戦略がUC不適合症の管理における潜在的な役割を果たすことを示唆している.
関連する概念動画
01:29Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
308
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
308
01:17Drugs for Treatment of Diarrhea-Predominant IBS
289
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
289
01:29Inflammatory Bowel Disease IV: Pharmacological Management
177
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
177
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
200
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
200
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
264
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264